HMOX1 and neoplasm: Work by Muliaditan and colleagues shed light on the potential role of HO-1 as an immune checkpoint proposing tin-mesoporphyrin (SnMP) as a novel immune checkpoint inhibitor to be used in combination with chemotherapy allowing immunological control of tumor growth in different preclinical models of BC.